Abstract:
The present invention provides an agent, or composition containing an agent, for use in treating or preventing hypercytokinemia in a subject resulting from cytokine release from non-proliferating immune cells in blood, wherein the agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents. In other aspects of the invention agents and compositions of the invention may be used in conjunction with one or more additional active agents, such as kinase inhibitors.
Abstract:
The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents. In other aspects of the invention agents and compositions of the invention may be used in conjunction with one or more additional active agents, such as antibiotics.
Abstract:
A composition of matter comprising a plurality of nanowires on a substrate, said nanowires having been grown epitaxially on said substrate in the presence of a metal catalyst such that a catalyst deposit is located at the top of at least some of said nanowires, wherein said nanowires comprise at least one group III-V compound or at least one group II-VI compound or comprises at least one non carbon group IV element; and wherein a graphitic layer is in contact with at least some of the catalyst deposits on top of said nanowires.
Abstract:
A wave energy convertor for extracting energy from ocean waves. The wave energy convertor may include a buoy arranged to oscillate relative to a reference point about an equilibrium position and a negative spring device connected between the buoy and the reference point, wherein the negative spring device is for applying a positive force in the direction of displacement when the buoy moves away from the equilibrium position.
Abstract:
A composition of matter comprising at least one nanowire on a graphitic substrate, said at least one nanowire having been grown epitaxially on said substrate, wherein said nanowire comprises at least one group III-V compound or at least one group II-VI compound or comprises at least one non carbon group (IV) element.
Abstract:
A guidance device for guidance of surgical interventions on a patient, the surgical interventions requiring an intervention device to surgically enter the body and be directed through body tissues to a target site within the patient's head, the guidance device comprising: a guide piece 4 for guiding the intervention device and directing it to the target site within the patient's head; a mouthpiece 2 arranged to anchor the device in a fixed orientation relative to the patient's upper jaw or lower jaw; and a targeted or targetable mounting 6 supporting the guide piece on the mouthpiece, the mounting 6 being for directing the guide piece 4 in a desired orientation relative to the mouthpiece 2 to thereby direct the intervention device through body tissues to the target site in the patient's head.
Abstract:
The present invention relates to chimeric anti-CD14 antibodies and methods of using the same. In some embodiments, the present invention relates to the use of chimieric anti-CD 14 antibodies in research, diagnostic, and therapeutic applications. In one embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 1 and a variable heavy chain of SEQ ID NO: 2 (isolated from the hybridoma clone 18D11). In another embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 3 and a variable heavy chain of SEQ ID NO: 4 (isolated from the hybridoma clone Mil2).
Abstract:
A membrane suitable for separating a gas from a gas mixture comprising a non cross-linked PVAm having a molecular weight of at least Mw 100,000 carried on a support wherein after casting onto the support, said PVAm has been heated to a temperature in the range 50 to 150° C., e.g. 80 to 120° C.
Abstract:
A neuroinhibitory substance for use in a method for treating or preventing headache comprising injecting a neuroinhibitory substance such as botulinium toxin in close proximity to the sphenopalatine ganglion or otic ganglion wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically and the neuroinhibitory substance injected in close proximity to the SPG or OG.
Abstract:
A composition of matter comprising a film on a graphitic substrate, said film having been grown epitaxially on said substrate, wherein said film comprises at least one group III-V compound or at least one group II-VI compound.